Jun 29 |
With 50% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing
|
Jun 8 |
What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing?
|
Jun 6 |
Fulgent Genetics: Growth Is Returning
|
Jun 3 |
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
|
May 24 |
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
|
May 15 |
Moffitt and Fulgent Pharma partner on personalised cancer therapies
|
May 14 |
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
|
May 6 |
Fulgent Genetics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
May 4 |
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript
|
May 4 |
Fulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...
|